Q32 Bio Inc. 8K

Q32 Bio reported Q2 2026 results, positive Phase 2a bempikibart data in alopecia areata, a $200 million July 2026 equity offering, and sufficient cash runway through planned Phase 3 topline results.

Q32 Bio Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and provide a corporate update, highlighting positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe and very severe alopecia areata, continued enrollment in an open-label extension and plans to initiate a registration-directed program in 1H 2027 pending regulatory discussions in late 2026, advancement of a half-life extended anti-IL-7Rα antibody candidate ADX-914-XL in preclinical development, completion of a $200 million public offering in July 2026, and disclosure that its $106.3 million in cash and cash equivalents at June 30, 2026 plus offering proceeds are expected to fund operations through Phase 3 topline results from the planned registration-directed program, alongside reporting a quarterly net loss of $8.9 million.

Filing Facts

CIK

1661998

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-333813

Alert Tier

7